Welcome to our dedicated page for BioSig Technologies news (Ticker: BSGM), a resource for investors and traders seeking the latest updates and insights on BioSig Technologies stock.
BioSig Technologies Inc. (NASDAQ: BSGM) provides cutting-edge solutions in cardiac electrophysiology through its flagship PURE EP™ System. This page serves as the definitive source for official company news, including financial results, regulatory milestones, and clinical advancements.
Investors and healthcare professionals will find curated updates on product innovations, partnership announcements, and peer-reviewed research validating BioSig's signal processing technology. Key coverage areas: quarterly earnings reports, FDA clearances, hospital adoption metrics, and intellectual property developments.
All content undergoes strict verification to ensure alignment with SEC disclosure standards and medical device reporting regulations. Bookmark this page for real-time updates on BSGM's progress in enhancing cardiac ablation accuracy through advanced signal visualization technology.
BioSig Technologies (NASDAQ: BSGM) announced the appointment of Edwin Wang to its Advisory Board on March 27, 2023. Wang brings over 20 years of experience in private equity and venture capital, having founded Accretive Capital Partners LLC, which raised a top-quartile secondary direct investment fund. He previously directed the restructuring of a $1 billion venture capital portfolio at Asymmetry Capital LLC. His expertise is expected to enhance BioSig's capital markets strategy. BioSig's PURE EP™ System is gaining traction in the electrophysiology market, which is projected to reach $16 billion by 2028, aiming to improve patient outcomes and reduce healthcare costs.
BioSig Technologies, Inc. (NASDAQ: BSGM) has appointed Lorraine Spurge to its Advisory Board to enhance business development and access to capital. Ms. Spurge has a 40-year history in finance, having helped raise over $200 billion for growth companies. Her experience includes roles at Drexel Burnham Lambert and various entrepreneurial ventures. BioSig aims to leverage her expertise as it seeks to expand its shareholder base and advance growth initiatives. The company’s PURE EP™ System, an FDA-cleared device for cardiac procedures, is seeing commercial launch in prominent healthcare facilities, with a projected growth rate for the electrophysiology market at 11.2% by 2028.
BioSig Technologies, Inc. (NASDAQ: BSGM) announced it holds no cash or accounts at Silicon Valley Bank and has no business relationship with the bank. The company's PURE EP™ System, approved by the FDA, enhances cardiac signal visualization, making procedures more efficient. This system is being adopted by major healthcare institutions like Mayo Clinic and Cleveland Clinic. A recent study found that electrophysiologists rated the PURE EP™ System as equivalent or superior to conventional systems for 93.6% of signal samples. The global electrophysiology market is projected to reach $16 billion by 2028, growing at 11.2% annually.
FAQ
What is the current stock price of BioSig Technologies (BSGM)?
What is the market cap of BioSig Technologies (BSGM)?
